Skip to main content
. Author manuscript; available in PMC: 2018 Apr 27.
Published in final edited form as: Nature. 2017 Sep 20;550(7676):407–410. doi: 10.1038/nature24268

Extended Data Figure 8. Activities and specificities of high-fidelity SpCas9 variants targeted to endogenous human cell sites.

Extended Data Figure 8

a, On-target activities of WT SpCas9, SpCas9-HF1, Cluster 1 and Cluster 2 variants across 24 endogenous human genes, assessed by T7E1 assay; mean and s.e.m. shown; n = at least 3 biologically independent samples (overlaid as white circles). b, WT-normalized endogenous gene disruption data from panel a, for Cluster 1 and 2 variants. Error bars represent median and interquartile ranges of 24 biologically independent samples with the >70% interval of WT activity highlighted in light grey; Cluster 1 (HypaCas9) data from Fig. 3b is replotted for comparison. c–e, Summary of single mismatch tolerance of WT SpCas9, SpCas9-HF1, eSpCas9(1.1), and Cluster 1 and Cluster 2 variants on c, FANCF site 1 d, FANCF sites 4 and 6, and e, FANCF site 2. Percent modification in panels c–e assessed by T7E1 assay; mean and s.e.m. shown for n = at least 3 biologically independent samples (overlaid as white circles).